The fund primarily aims to generate significant capital appreciation for investors over an extended timeframe. To achieve this, it commits at least 80% of its overall assets to equity instruments, predominantly common stocks, of companies engaged in the health sciences and related fields. This specialized sector encompasses a broad spectrum of businesses, such as those involved in medical equipment and supplies, healthcare service delivery, advanced biotechnology, and pharmaceutical manufacturing. The portfolio maintains a concentrated investment approach, allocating more than 25% of its holdings to these health sciences and associated industries, and it also retains the flexibility to invest in companies based outside the United States.
Sector exposure data isn't available for this fund yet.
Holdings data isn't available for this fund yet.
